ClinicalTrials.gg
RecruitingNCT06940128DICER-aLVOUpdated Apr 27, 2026

Direct Ischemic Conditioning for Endovascular Recanalization for Anterior Large Vessel Occlusion (DICER-aLVO)

An interventional study of Direct Ischemic Conditioning A and Direct Ischemic Conditioning B in Ischemic Stroke, sponsored by General Hospital of Shenyang Military Region. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-27.

Sponsored by General Hospital of Shenyang Military Region · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Ischemic Stroke by General Hospital of Shenyang Military Region — 16 open to participants now, 16 under way, 1 of them phase 3. Ischemic Stroke · General Hospital of Shenyang Military Region.

Planned enrollment
16th of 27
120 · median 145
Started
2025
with 4 others
No phase
11 of 34
6 open now
Primary completion
2027-01
later than 3 of 15 live
Registered
27th of 34
by date

Among the 34 studies in Ischemic Stroke by General Hospital of Shenyang Military Region, this one is the 16th largest by planned enrollment of the 27 interventional ones that give a count, is one of 5 that started in 2025, is one of 11 with no phase, reaches primary completion later than 3 of the 15 other live ones, and was the 27th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

16 of the 34 studies in Ischemic Stroke by General Hospital of Shenyang Military Region are open now, in 1 country. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Where they have run

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Ischemic Stroke by General Hospital of Shenyang Military Region, or all of them as a file.
02

Study summary

Acute ischemic stroke (AIS) is the most common type of stroke, with high incidence rate and mortality. Endovascular therapy is currently the most effective treatment for AIS with large vessel occlusion, but only about 50% of patients achieve good outcome after endovascular therapy, while 50% of patients have poor prognosis, commonly referred to as ineffective perfusion. Therefore, how to improve ineffective perfusion is currently a hot topic.

Numerous studies have shown that Remote Ischemic Therapy (RIC) has a protective effect on ischemic stroke. Our recent RICAMIS study has demonstrated that RIC can significantly improve the functional prognosis of moderate acute ischemic stroke. Furthermore, direct ischemic conditioning has also showed neuroprotective effect. For example, in a rat model, within 2 minutes after reperfusion, using three cycles of 30 s reperfusion and 10 s occlusion for direct ischemic conditioning can effectively alleviate hyperperfusion and reduce cerebral infarction volume. Meanwhile, in previous clinical exploration studies, it was found that even induction by 5-minute ischemia and 5-minute reperfusion for up to 4 cycles is safe, feasible, and well tolerated for AIS patients receiving endovascular treatment. Immediate control of bilateral carotid artery blood flow after ischemia-reperfusion can significantly reduce cerebral infarction area and brain edema, and improve neurological function recovery in rats. Subsequent molecular mechanism studies have shown that direct ischemic conditioning can reduce the production of free radicals after cerebral ischemia-reperfusion, inhibit inflammatory reactions and cell apoptosis, downregulate the expression of signaling molecules mediating brain edema, promote Akt survival pathway, and improve the integrity of the blood-brain barrier, thereby exerting neuroprotective effects. Recent studies have also confirmed the safety and feasibility of direct ischemic conditioning for stroke patients achieving successful recanalization. More importantly, a recent cohort study has shown that direct ischemic conditioning can reduce infarct growth and brain edema after reperfusion in patients with AIS who have undergone thrombectomy for occlusion of large blood vessels in the anterior circulation, and improve prognosis after 90 days.

Based on the above discussion, this trial aims to evaluate the effectiveness and safety of direct ischemic conditioning for patients with AIS who have undergone thrombectomy for occlusion of large blood vessels in the anterior circulation.

03

Conditions studied

  • Ischemic Stroke

Keywords

  • Direct Ischemic Conditioning
  • stroke
  • Endovascular Recanalization
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-1. Over 18 years old; 2. The time from onset to randomization is less than 24 hours; 3. Patients with acute anterior artery occlusion and receiving successful recanalization (mTICI 2b-3) after endovascular treatment and with residual stenosis ≤ 50%; 4. Cerebral circulation time after successful recanalization: affected side ≤ healthy side; 5. PH2 hemorrhage was excluded by immediate postoperative CT examination; 6. Re-onset patients with first onset or past onset without sequelae such as limb paralysis should not affect the score of this NIHSS, and mRS Score of patients with past onset should be less than 2 points; 7. Signed by patient or their legally authorized representative.

Exclusion criteria

Exclusion Criteria:

- 1. Spherical enlargement of the lesion site twice or more; 2. Proximal residual stenosis >50% for patients with tandem lesions; 3. Intracranial hemorrhagic diseases: cerebral hemorrhage, subarachnoid hemorrhage, etc.

4. Chronic liver disease, liver and kidney insufficiency, elevated or AST (greater than 2 times the ), elevated serum creatinine (greater than 1.5 times the upper limit of normal) or dependent on kidney dialysis; 5. Women who are pregnant, have a pregnancy plan or are breastfeeding; 6. Combined with serious other diseases, \< 6 months; 7. Other conditions deemed inappropriate for participation in this study.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Direct Ischemic Conditioning Group A

    The protocol comprised 5 cycles of 30-s balloon inflations and 30-s deflations.

    Procedure: Direct Ischemic Conditioning A

  • Experimental
    Direct Ischemic Conditioning Group B

    The protocol comprised 4 cycles of 60-s balloon inflations and 60-s deflations.

    Procedure: Direct Ischemic Conditioning B

  • Experimental
    Direct Ischemic Conditioning Group C

    The protocol comprised 3 cycles of 120-s balloon inflations and 120-s deflations.

    Procedure: Direct Ischemic Conditioning C

  • No intervention
    Control group

Interventions

  • ProcedureDirect Ischemic Conditioning A

    Direct Ischemic Conditioning initiated within 5 minutes post-revascularization using either a balloon guiding catheter or a balloon catheter, positioned at the C1 segment of the ipsilateral internal carotid artery (ICA) to temporarily halt antegrade flow. The protocol comprised 5 cycles of 30-s balloon inflations and 30-s deflations.

  • ProcedureDirect Ischemic Conditioning B

    Direct Ischemic Conditioning initiated within 5 minutes post-revascularization using either a balloon guiding catheter or a balloon catheter, positioned at the C1 segment of the ipsilateral internal carotid artery (ICA) to temporarily halt antegrade flow. The protocol comprised 4 cycles of 60-s balloon inflations and 60-s deflations.

  • ProcedureDirect Ischemic Conditioning C

    Direct Ischemic Conditioning initiated within 5 minutes post-revascularization using either a balloon guiding catheter or a balloon catheter, positioned at the C1 segment of the ipsilateral internal carotid artery (ICA) to temporarily halt antegrade flow. The protocol comprised 3 cycles of 120-s balloon inflations and 120-s deflations.

06

What researchers measure

Primary outcomes

  1. Proportion of patients with modified Rankin Score (mRS) 0 to 2

    mRS ranges from 0-6, higher scores mean a worse outcome

    Time frame: at 90±7 days

Secondary outcomes

  1. distribution of modified Rankin Score (mRS)

    mRS ranges from 0-6, higher scores mean a worse outcome

    Time frame: at 90±7 days

  2. Proportion of patients with modified Rankin Score (mRS) 0 to 1

    mRS ranges from 0-6, higher scores mean a worse outcome

    Time frame: at 90±7 days

  3. Proportion of early neurological improvement

    early neurological improvement was defined as a 4 point or greater decrease in National Institute of Health stroke scale (NIHSS). NIHSS range from 0-42, higher scores mean a worse outcome

    Time frame: at 24 (-6/+24) hours

  4. Change in National Institute of Health stroke scale (NIHSS) score

    NIHSS range from 0-42, higher scores mean a worse outcome

    Time frame: at 24 (-6/+24) hours

  5. Change in National Institute of Health stroke scale (NIHSS) score

    NIHSS range from 0-42, higher scores mean a worse outcome

    Time frame: at 10±2 days

  6. The amount of contrast exudation after treatment (CT assessment)

    Time frame: at 24 (-6/+24) hours

  7. The amount of midline shift of the brain on neuroimaging after treatmet

    Time frame: at 24 (-6/+24) hours

  8. Changes in brain circulation time after treatment (between healthy side and affected side, before and after treatment of affected side ischemia)

    Time frame: immediately after treatment

  9. Recurrent stroke and new cardiovascular and cerebrovascular events

    Time frame: at 90±7 days

  10. Proportion of balloon treatment-related complications (responsible vessel re-occlusion, vagal reflex, dissection, plaque shedding, and vasospasm during and after treatment)

    Time frame: immediately after treatment

  11. Proportion of symptomatic intracranial hemorrhage

    Time frame: at 24 (-6/+24) hours

  12. Proportion of occurrence of cerebral parenchymal hemorrhage types (PH1) and (PH2)

    Time frame: at 24 (-6/+24) hours

  13. Proportion of serious adverse events

    Time frame: at 24 (-6/+24) hours

  14. Proportion of all-cause deaths

    Time frame: at 10 days

Other outcomes

  1. Changes in serum biomarkers

    Time frame: at 24 (-6/+24) hours

  2. Changes in cerebral blood flow autoregulation ability

    Time frame: at 24 (-6/+24) hours

07

Study locations

1 of 1 sites recruiting
  • General Hospital of Northern Theater Command
    Shengyang, Liaoning 110016, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Jan 2027, 21 months after the start.

Of 576 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 21 months is below that.

Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2025
First posted
Apr 23, 2025
StartActual
Mar 31, 2025
Primary completionEst.
Jan 1, 2027
CompletionEst.
Mar 31, 2027
Last update
Apr 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06940128
Lead sponsor
General Hospital of Shenyang Military Region
Responsible party
Hui-Sheng Chen (Director, General Hospital of Shenyang Military Region) — Principal investigator
First posted
Apr 23, 2025
Start date
Mar 31, 2025
Primary completion
Jan 1, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Apr 27, 2026

Study contacts

Hui-Sheng Chen
Contact
chszh@aliyun.com
+86-024-28897511

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion